



## Curriculum Vitae

### Personal information Christian Gisselbrecht

#### Work experience

---

1. Employer: hôpital Saint Louis Paris VII university
  - Start date: 091981
  - End date: 092010
  - Position: professor hematology, head hematology oncology department
  - Activities: treatment lymphoma stem cell transplantation clinical research: phase 1, 2,3 studies chair : multicentric and international studies
  - Country: France
2. Employer: hopital saint louis Paris VII university
  - Start date: 091975
  - End date: 091981
  - Position: chief resident hematology
  - Activities: treatments of hematologic malignancies pharmacology of antineoplastic agents
  - Country: France
3. Employer: non profit association GELA
  - Start date: 111987
  - End date: 102003
  - Position: president
  - Activities: organization of clinical studies among 100 centers France and Belgium for all type of lymphoma. Phase 2, 3
  - Country: France

#### Education and training

---

1. Subject: hôpital saint louis paris VII university
  - Start date: 111969
  - End date: 101975
  - Qualification: MD. 1975 resident hematology oncology
  - Organisation: medical training in hematology treatment of lymphoma, leukemia stem cell transplantation CAR T
  - Country: France
2. Subject: Paris VII university of sciences
  - Start date: 091971
  - End date: 071972
  - Qualification: certificate of molecular biology
  - Organisation: training in molecular biology
  - Country: France
3. Subject: national institute of health (NIH) Bethesda
  - Start date: 091972
  - End date: 021974
  - Qualification: visiting research associate
  - Organisation: mechanisms of enzymes activation by the liver drugs metabolism
  - Country: United States
4. Subject: Paris VII university Diderot
  - Start date: 091981
  - End date: 102010
  - Qualification: full professor hematology
  - Organisation: University teaching for graduate or post\_graduate, medical students in Hematology, Seminars \_ Oncology \_ Hematology for post\_Doctorat students, Director of thesis. Research focus on clinical studies in hematology
  - Country: France
5. Subject: Hospital Saint Louis, Institut Hematologie
  - Start date: 092010
  - End date:
  - Qualification: emeritus professor hematology
  - Organisation: treatment of lymphoma, stem cell transplantation car T cells conference invited speakers
  - Country: France

#### Additional information

---

##### Publications

PUBLICATIONS from 2021 – 2009 ( >300 in medline) . Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, Garcia\_Ochoa B, Enzmann H, Gisselbrecht C, Delgado J, Pignatti F. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma Oncologist. 2021 Jan;26(1):70\_76. doi: 10.1002/onco.13592. Epub 2020 Nov 23.PMID: 33179377 Free PMC article. Clinical Trial. Delgado J, Voltz C, Stain M, Balkowiec\_Iskra E, Mueller B, Wernsperger J, Malinowska I, Gisselbrecht C, Enzmann H, Pignatti F. The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion\_dependent Anemia Caused by Low\_risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta\_thalassemia. Hemasphere. 2021 Jul 19;5(8):e616. doi: 10.1097/HS9.0000000000000616. eCollection 2021 Aug.PMID: 34291195 Free PMC article. Review. Delgado J, Voltz C, Stain M, Lapveteläinen T, Urach S, Lähteenvuo J, Penttilä K, Gisselbrecht C, Enzmann H, Pignatti F. The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso\_Occlusive Crises in Patients With Sickle Cell Disease. Hemasphere. 2021 Jun

28;5(7):e604. doi: 10.1097/HS9.0000000000000604. eCollection 2021 Jul.PMID: 34235401 Free PMC article. Review. Delgado J, Zienowicz M, van Hennik PB, Moreau A, Gisselbrecht C, Enzmann H, Pignatti F. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. *Oncologist*. 2021 Nov;26(11):983-987. doi: 10.1002/onco.13892. Epub 2021 Jul 19.PMID: 34213061 Delgado J, Voltz C, Stain M, Lapveteläinen T, Urach S, Lähteenvuo J, Penttälä K, Gisselbrecht C, Enzmann H, Pignatti F. The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso\_Occlusive Crises in Patients With Sickle Cell Disease. *Hemasphere*. 2021 Jun 28;5(7):e604. doi: 10.1097/HS9.0000000000000604. eCollection 2021 Jul.PMID: 34235401 Free PMC article. Review. Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jenny J. Kim, and Christian Gisselbrecht . Comparison of 2\_year outcomes with CAR T cells (ZUMA\_1) vs salvage chemotherapy in refractory large B\_cell lymphoma. *blood advances* 26 OCTOBER 2021 • VOLUME 5, NUMBER 20 ;https://doi.org/10.1182/bloodadvances.2020003848 Gita Thanarajasingam1, Lori M Minasian2, Vishal Bhatnagar3, Franco Cavalli4, R Angelo De Claro3, Amylou C Dueck5, Tarec C El Galaly6, Neil Everest7, Jan Geissler8, Christian Gisselbrecht9, Nicole Gormley3, John Gribben10, Mary Horowitz11, S Percy Ivy2, Caron A Jacobson12, Armand Keating13, Paul G Kluetz3, Yok Lam Kwong14, Richard F Little2, Matthew J Matasar15, Maria\_Victoria Mateos16, Kristen McCullough1, Robert S Miller17, Mohamad Mohty18, Philippe Moreau19, Lindsay M Morton2, Sumimasa Nagai20, Abhilasha Nair3, Loretta Nastoupil21, Kaye Robertson22, Surbhi Sidana23, Karin E Smedby24, Pieter Sonneveld25, Kyriaki Tzoganis26, Flora E van Leeuwen27, Galina Velikova28, Diego Villa29, John R Wingard30, John F Seymour31, Thomas M Habermann. Moving Beyond Maximum Grade: Progress Towards Modernising the Assessment and Reporting of Adverse Events in Haematological Malignancies *Lancet Haematology* 2021 Commission Follow Up in press. Ali S, Kjeker R, Niederlaender C, Markey G, Saunders TS, Opsata M, Moltu K, Bremnes B, Grønevik E, Muusse M, Håkonsen GD, Skibeli V, Kalland ME, Wang I, Buajordet I, Urbaniak A, Johnston J, Rantell K, Kerwash E, Schuessler\_Lenz M, Bergh J, Gisselbrecht C, Tzoganis K, Papadoulis I, Pignatti F. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B\_Cell Lymphoma. *Oncologist*. 2020 Feb;25(2):e321\_e327. doi: 10.1634/theoncologist.2019\_0233. Epub 2019 Oct 16.PMID: 32043764 Ali S, Moreau A, Melchiorri D, Camarero J, Josephson F, Olimpiero O, Bergh J, Karres D, Tzoganis K, Gisselbrecht C, Pignatti F. Blnatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T\_Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. *Oncologist*. 2020 Apr;25(4):e709\_e715. doi: 10.1634/theoncologist.2019\_0559. Epub 2019 Nov 14.PMID: 32297447 Tzoganis K, Røshol H, Olsen HH, Aas IB, Dalhus ML, Håkonsen GD, Nilssen LS, Lindberg V, Økvist M, Bolstad B, Rogovska I, Karpova N, Enzmann H, Gisselbrecht C, Pignatti F. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation. *Oncologist*. 2020 Jul;25(7):e1070\_e1076. doi: 10.1634/theoncologist.2019\_0976. Epub 2020 Mar 10.PMID: 32154636 Papadoulis I, Mueller\_Berghaus J, Beuneu C, Ali S, Hofner B, Petavy F, Tzoganis K, Miermont A, Norga K, Kholmanskikh O, Leest T, Schuessler\_Lenz M, Salmonson T, Gisselbrecht C, Garcia JL, Pignatti F. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B\_Cell Lymphoma. *Oncologist*. 2020 Oct;25(10):894\_902. doi: 10.1634/theoncologist.2019\_0646. Epub 2020 Apr 27.PMID: 32339368 Lansigan F, Horwitz SM, Pinter\_Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T\_Cell Lymphoma Patients after Front\_Line Therapy from the COMPLETE Registry. *Acta Haematol*. 2020;143(1):40\_50. doi: 10.1159/000500666. Epub 2019 Jul 17.PMID: Gribben J, Macintyre E, Sonneveld P, Doorduyn J, Gisselbrecht C, Jäger U, Le Gouill S, Rule S, Dreyling M. Reducing Bureaucracy in Clinical Research: A Call for Action. *Hemasphere*. 2020 Feb 26;4(2):e352. doi: 10.1097/HS9.0000000000000352. eCollection 2020 Apr.PMID: 32309789 Sureda A, André M, Borchmann P, da Silva MG, Gisselbrecht C, Vassilakopoulos TP, Zinzani PL, Walewski J. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. *BMC Cancer*. 2020 Nov 10;20(1):1088. doi: 10.1186/s12885\_020\_07561\_2.PMID: 33172440 Lansigan F, Horwitz SM, Pinter\_Brown LC, Carson KR, Shustov AR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Foss FM. Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. *Clin Lymphoma Myeloma Leuk*. 2020 Nov;20(11):744\_748. doi: 10.1016/j.clml.2020.05.001. Epub 2020 May 11.PMID: 32532611 Lansigan F, Horwitz SM, Pinter\_Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T\_Cell Lymphoma Patients after Front\_Line Therapy from the COMPLETE Registry. *Acta Haematol*. 2020;143(1):40\_50. doi: 10.1159/000500666. Epub 2019 Jul 17.PMID: 31315113 Free article. Tzoganis K, Røshol H, Olsen HH, Aas IB, Dalhus ML, Håkonsen GD, Nilssen LS, Lindberg V, Økvist M, Bolstad B, Rogovska I, Karpova N, Enzmann H, Gisselbrecht C, Pignatti F. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation. *Oncologist*. 2020 Jul;25(7):e1070\_e1076. doi: 10.1634/theoncologist.2019\_0976. Epub 2020 Mar 10.PMID: 32154636 Free PMC article. Review. Assouline S, Li S, Gisselbrecht C, Fogarty P, Hay A, van den Neste E, Shepherd LE, Schmitz N, Baetz T, Keating A, Robinson S, Seftel M, Stelitano C, Djurfeldt MS, Meyer R, Chen BE, Crump M. The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. *Blood Adv*. 2020 May 12;4(9):2011\_2017. doi: 10.1182/bloodadvances.2020001646.PMID: 32396614 Delgado J, Josephson F, Camarero J, Garcia\_Ochoa B, Lopez\_Anglada L, Prieto\_Fernandez C, van Hennik PB, Papadoulis I, Gisselbrecht C, Enzmann H, Pignatti F. EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. *Oncologist*. 2021 Mar;26(3):242\_249. doi: 10.1002/onco.13685. Epub 2021 Feb 10.PMID: 33486852 Review. Ali S, Moreau A, Melchiorri D, Camarero J, Josephson F, Olimpiero O, Bergh J, Karres D, Tzoganis K, Gisselbrecht C, Pignatti F. Blnatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T\_Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. *Oncologist*. 2020 Apr;25(4):e709\_e715. doi: 10.1634/theoncologist.2019\_0559. Epub 2019 Nov 14.PMID: 32297447 Free PMC article. Schmitz N, Truemper LH, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner\_Drouet EM, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Rousset M, Kroschinsky FP, Lindemann WW, Dreger P, Viardot A, Milpied NJ, Gisselbrecht C, Wulf GG, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer AJ, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Bräulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O. A randomized phase 3 trial of auto vs. allo transplantation as part of first\_line therapy in poor\_risk peripheral T\_NHL. *Blood*. 2020 Dec 17;blood.2020008825. doi: 10.1182/blood.2020008825. Online ahead of print.PMID: 33512419 Park SI, Horwitz SM, Foss FM, Pinter\_Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR. The role of autologous stem cell transplantation in patients with nodal peripheral T\_cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. *Cancer*. 2019 Jan 29. doi: 10.1002/cncr.31861. [Epub ahead of print] Gisselbrecht C. An unmet need for long\_term follow\_up in Hodgkin's lymphoma? *Lancet Haematol*. 2018 Oct;5(10):e435\_e436. doi: 10.1016/S2352\_3026(18)30150\_9. Positron Emission Tomography\_Guided Therapy of Aggressive Non\_Hodgkin Lymphoma: Standard of Care After the PETAL Study? *Gisselbrecht C J Clin Oncol*. 2018 Sep 17;JCO1800498. doi: 10.1200/JCO.18.00498. [Epub ahead of print] No abstract available. New perspectives in the therapeutic approach of peripheral T\_cell lymphoma. *Gisselbrecht C, Sibon D. Curr Opin Oncol*. 2018 Sep;30(5):285\_291. doi: 10.1097/CCO.0000000000000469. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. *Thanarajasingam G, Minasian LM, Cavalli F, De Claro RA, Dueck AC, El Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzoganis K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. *Lancet Haematol*. 2018 Jun 12. pii: S2352\_3026(18)30051\_6. doi: 10.1016/S2352\_3026(18)30051\_6. [Epub ahead of print] Review. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. *Gisselbrecht C, Van Den Neste E. Br J Haematol*. 2018 Sep;182(5):633\_643. doi: 10.1111/bjh.15412. Epub 2018 May 29. Review. Tzoganis K, Camarero Jimenez J, Garcia I, Sancho\_Lopez A, Martin M, Moreau A, Demolis P, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. *Oncologist*. 2017 Sep 21. pii:*

theoncologist.2017\_0184. doi: 10.1634/theoncologist.2017\_0184. Kharfan\_Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Samvati BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2017 Aug 7. pii: S1083\_8791(17)30623\_7. doi: 10.1016/j.bbmt.2017.07.027 Hsi ED, Horwitz SM, Carson KR, Pinter\_Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Colлие AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. *Clin Lymphoma Myeloma Leuk*. 2017 Apr;17(4):193\_200. doi: 10.1016/j.clml.2016.10.001. Carson KR, Horwitz SM, Pinter\_Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. *Cancer*. 2017 Apr 1;123(7):1174\_1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruwilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wieszorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR\_1 study. *Blood*. 2017 Oct 19;130(16):1800\_1808. doi: 10.1182/blood\_2017\_03\_769620. Epub 2017 Aug 3. Erratum in: *Blood*. 2018 Feb 1;131(5):587\_588. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M, Ribrag V, Dührsen U, Ma D, Briere J, Thieblemont C, Bachy E, Moskowitz CH, Glass B, Gisselbrecht C. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. *Bone Marrow Transplant*. 2017 Feb;52(2):216\_221. doi: 10.1038/bmt.2016.213. Epub 2016 Sep 19. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M, Ribrag V, Dührsen U, Ma D, Briere J, Thieblemont C, Bachy E, Moskowitz CH, Glass B, Gisselbrecht C. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. *Bone Marrow Transplant*. 2016 Sep 19. Gisselbrecht C. Is nivolumab an option for Hodgkin's lymphoma? *Lancet Oncol*. 2016 Sep;17(9):1183\_4. Broséus J, Chen G, Hergalant S, Ramstein G, Mounier N, Guéant JL, Feugier P, Gisselbrecht C, Thieblemont C, Houlgatte R. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. *Oncotarget*. 2016 Jun 2. Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, Legoff M, Biau D, Anract P, Roux C, Blanc\_Autran E, Delarue R, Gisselbrecht C, Ketterer N, Recher C, Bonnet C, Peyrade F, Haioun C, Tilly H, Salles G, Brice P, Bouscary D, Deau B, Tamburini J. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. *Leuk Lymphoma*. 2016 Dec;57(12):2820\_2826. Nieto M, Demolis P, Béhanzin E, Moreau A, Hudson I, Flores B, Stemplewski H, Salmonson T, Gisselbrecht C, Bowen D, Pignatti F. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. *Oncologist*. 2016 Jun;21(6):692\_700. Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. *Ann Oncol*. 2016 Mar;27(3):390\_7. Gravani I, Tzozani K, van Hennik P, de Graeff P, Schmitt P, Mueller\_Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. *Oncologist*. 2016 Jan;21(1):102\_9. 26621039. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. *Bone Marrow Transplant*. 2016 Jan;51(1):51\_7. de Leval L, Parrens M, Le Bras F, Jais JP, Fataccioli V, Martin A, Lamant L, Delarue R, Berger F, Arbion F, Bossard C, Copin MC, Canioni D, Charlotte F, Damaj G, Dartigues P, Fabiani B, Ledoux\_Pilon A, Montagne K, Molina T, Patey M, Tas P, Peoch M, Petit B, Petrella T, Picquenet JM, Rousset T, Rousselet M, Soubeyran I, Thiebault S, Tournilhac O, Xerri L, Gisselbrecht C, Haioun C, Delsol G, Gaulard P. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. *Haematologica*. 2015 Sep;100(9):e361\_4. Hess G, Coiffier B, Crump M, Gisselbrecht C, Offner F, Romaguera J, Kang L, Moran E. Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis. *PJ. Exp Hematol Oncol*. 2015 Apr 11;4:11. Wagner\_Johnston ND, Goy A, Rodriguez MA, Ehmann WC, Hamlin PA, Radford J, Thieblemont C, Suh C, Sweetenham J, Huang Y, Sullivan ST, Vandendries ER, Gisselbrecht C. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2015;56(10):2863\_9. Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho\_Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. 2015 Mar;20(3):329\_34. Mounier N, Gisselbrecht C. Decision\_making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. *Expert Rev Hematol*. 2015 Apr;8(2):205\_16. Gisselbrecht C. Should we replace dexamethasone, cytarabine, and cisplatin for relapsed lymphoma? *J Clin Oncol*. 2014; 32(31):3472\_3. Gisselbrecht C. Futility of relapsed diffuse large B cell lymphoma transplantation? *Biol Blood Marrow Transplant*. 2014; 20(11):1667\_9. E. Bordessoule D, Bouabdallah R, Delmer A, Casasnovas RO, Ysebaert L, Ciappuccini R, Briere J, Gisselbrecht C. Upfront consolidation combining yttrium\_90 ibritumomab tiuxetan and high\_dose therapy with stem cell transplantation in poor\_risk patients with diffuse large B cell lymphoma. *Fruchart C, Tilly H, Morschhauser F, Ghesquières H, Bouteloup M, Fermé C, Van Den Neste Biol Blood Marrow Transplant*. 2014; 20(12):1905\_11. Bosly A, Grigg A, Holte H, Gisselbrecht C, Radford J, Rossi A, Lopez\_Guillermo A, Trneny M, Sebban C, Hagberg H, Leal da Costa F, Colombat P, Bron D, Coiffier B. A randomized study of interferon alpha\_2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. *Oncologist*. 2013; 18(11):1189. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, Caballero D, Tilly H, Walewski JA, Bence\_Bruckler I, To B, Geisler CH, Schots R, Kimby E, Taverna CJ, Kozák T, Dreger P, Uddin R, Ruiz de Elvira C, Goldstone AH. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. *J Clin Oncol*. 2013 May 1;31(13):1624\_30. Péan E, Flores B, Hudson I, Sjöberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. 2013;18(5):625\_33. doi: 10.1634/theoncologist.2013\_0020. Epub 2013 Apr 24. Gisselbrecht C. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? *Hematology Am Soc Hematol Educ Program*. 2012;2012:410\_6. doi: 10.1182/asheducation\_2012.1.410. Review Gisselbrecht C. TP53 mutations and rituximab\_CHOP. *Blood*. 2012 Nov 8;120(19):3867\_9. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, Salles G, Moskowitz CH, Glass B. Rituximab Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. *J Clin Oncol*. 2012 Dec 20;30(36):4462\_9. Mounier N, Gisselbrecht C. Relapses, treatments and new drugs. *Best Pract Res Clin Haematol*. 2012 Mar;25(1):49\_60. Gisselbrecht C. Preface. *Best Pract Res Clin Haematol*. 2012 Mar;25(1):1\_2. Ribrag V, Caballero D, Ferme C, Zucca E, Arranz R, Briones J, Gisselbrecht C, Salles G, Gianni AM, Gomez H, Kahatt C, Corrado C, Szyldergemajn S, Extremera S, de Miguel B, Cullell\_Young M, Cavalli F. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. *Haematologica*. 2013 Mar;98(3):357\_63. Sibon D, Fournier M, Brière J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H. Long\_Term Outcome of Adults With Systemic Anaplastic Large\_Cell Lymphoma Treated Within the Groupe d'Etude des Lymphomes de l'Adulte Trials. *J Clin Oncol*. 2012 Nov 10;30(32):3939\_46. Valleron W, Ysebaert L, Berquet L, Fataccioli V, Quelen C, Martin A, Parrens M, Lamant L, de Leval L, Gisselbrecht C, Gaulard P, Brousset

P. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T<sub>h</sub> cell lymphoma. *Blood*. 2012 Nov 8;120(19):3997. 4005 De Leval L, Bonnet C, Copie Bergman C, Seidel L, Baia M, Brière J, Molina TJ, Fabiani B, Petrella T, Bosq J, Gisselbrecht C, Siebert R, Tilly H, Haioun C, Fillet G, Gaulard P. Diffuse large B<sub>2</sub> cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. *Ann Oncol*. 2012 Dec;23(12):3143\_51. Gisselbrecht C. Current approaches to the treatment of non-Hodgkin's lymphoma. *Hematol Rep*. 2011 Oct 28;3(3s):e3. Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C, Cogliatti S, Hirchaud E, Ysebaert L, Bron D, Soulier J, Gaulard P, Houlgatte R, Gisselbrecht C, Thieblemont C. MYC+ diffuse large B<sub>2</sub> cell lymphoma is not salvaged by classical R<sub>1</sub>ICE or R<sub>1</sub>DHAP followed by BEAM plus autologous stem cell transplantation. *Blood*. 2012 May 17;119(20):4619\_24. Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A; Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT). High\_dose therapy and autologous stem cell transplantation in first relapse for diffuse large B<sub>2</sub> cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. *Biol Blood Marrow Transplant*. 2012 May;18(5):788\_93. Martis N, Gisselbrecht C, Mounier N. Quality of life following treatment for B<sub>2</sub> cell lymphoma. *Expert Rev Pharmacoecon Outcomes Res*. 2011 Oct;11(5):523\_32. Review. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C. The germinal center/activated B<sub>2</sub> cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B<sub>2</sub> cell lymphoma: a bio\_CORAL study. *J Clin Oncol*. 2011 Nov 1;29(31):4079\_87. Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesquières H, Bouabdallah K, Morschhauser F, Coiffier B, Le Gouill S, Bologna S, Delarue R, Huynh A, Bosly A, Brière J, Gisselbrecht C. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z<sub>2</sub>BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low\_grade CD20\_positive B<sub>2</sub> cell lymphoma. A GELA phase II prospective study. *Clin Lymphoma Myeloma Leuk*. 2011 Apr;11(2):212\_8. Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquières H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high\_risk diffuse large B<sub>2</sub> cell lymphoma for GELA. *Haematologica*. 2011 Aug;96(8):1136\_43. Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C, Gabarre J, Morschhauser F, Gisselbrecht C, Mounier N; Groupe d'Etude des Lymphomes de l'Adulte. Quality of life in 269 patients with poor\_risk diffuse large B<sub>2</sub> cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. *Leuk Lymphoma*. 2011 Jul;52(7):1239\_48. Gisselbrecht C. A revival: radioimmunotherapy in mucosa associated lymphoid tissue lymphoma. *Leuk Lymphoma*. 2011 Feb;52(2):159\_60. O'Connor OA, Pro B, Pinter Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T<sub>h</sub> cell lymphoma: results from the pivotal PROPEL study. *J Clin Oncol*. 2011 Mar 20;29(9):1182\_9. Mounier N, Gisselbrecht C. Stem cell transplantation for diffuse large B<sub>2</sub> cell lymphoma patients in the rituximab era. *Curr Opin Oncol*. 2011 Mar;23(2):209\_13. Review. Maloney D, Morschhauser F, Linden O, Hagenbeek A, Gisselbrecht C. Diversity in antibody\_based approaches to non-Hodgkin lymphoma. *Leuk Lymphoma*. 2010 Aug;51 Suppl 1:20\_7. Review. Morel P, Munck JN, Coiffier B, Gisselbrecht C, Ranta D, Bosly A, Tilly H, Quesnel B, Thyss A, Mounier N, Brière J, Molina T, Reyes F; Groupe d'Etude de Lymphomes des l'Adulte (GELA). Comparison of two high\_dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low\_intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93\_2 protocol. *Leuk Lymphoma*. 2010 Sep;51(9):1668\_77. Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J, Mounier N, Gisselbrecht C, Faure P, Thieblemont C. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R<sub>1</sub>DHAX) is an effective and safe salvage regimen in relapsed/refractory B<sub>2</sub> cell non-Hodgkin lymphoma. *Clin Lymphoma Myeloma Leuk*. 2010 Aug;10(4):262\_9. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B<sub>2</sub> cell lymphoma in the rituximab era. *J Clin Oncol*. 2010 Sep 20;28(27):4184\_90. Jardin F, Jais JP, Molina TJ, Parmentier F, Picqueton JM, Ruminy P, Bastard C, Salles GA, Feugier P, Thieblemont C, Gisselbrecht C, de Reynies A, Coiffier B, Haioun C, Leroy K. Diffuse large B<sub>2</sub> cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R<sub>1</sub>CHOP treatment: a GELA study. *Blood*. 2010 Aug 19;116(7):1092\_104. Advani A, Coiffier B, Czuczman M, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt\_Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B<sub>2</sub> cell non-Hodgkin's lymphoma: results of a phase I study. *J Clin Oncol*. 2010 Apr 20;28(12):2085\_93. Gisselbrecht C. Molecular signatures in T<sub>h</sub> cell lymphoma. *Blood*. 2010 Feb 4;115(5):919\_20. Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, Solal\_Celigny P, Salles G. Long\_term follow\_up of patients with newly diagnosed follicular lymphoma in the prirituximab era: effect of response quality on survival. A study from the groupe d'etude des lymphomes de l'adulte. *J Clin Oncol*. 2010 Feb 10;28(5):822\_9. De Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T<sub>h</sub> cell lymphoma. *Br J Haematol*. 2010 Mar;148(5):673\_89. Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. *Summary. Oncologist*. 2009;14 Suppl 2:52\_4. Review. Gisselbrecht C, Vose J, Nademane A, Gianni AM, Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. *Oncologist*. 2009;14 Suppl 2:41\_51. Review. Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignan M, Conti PS. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. *Oncologist*. 2009;14 Suppl 2:30\_40. Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. *Oncologist*. 2009;14 Suppl 2:4\_16. Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. *Introduction. Oncologist*. 2009;14 Suppl 2:1\_3. Copie Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, Salles GA, Berger F, Haioun C, Tilly H, Emile JF, Banham AH, Mounier N, Gisselbrecht C, Feugier P, Coiffier B, Molina TJ. Immuno\_fluorescence in situ hybridization index predicts survival in patients with diffuse large B<sub>2</sub> cell lymphoma treated with R<sub>1</sub>CHOP: a GELA study. *J Clin Oncol*. 2009 Nov 20;27(33):5573\_9. Herrlinger U, Glantz M, Schlegel U, Gisselbrecht C, Cavalli F. Should intra\_cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. *Semin Oncol*. 2009 Aug;36(4 Suppl 2):S25\_34. Review. Thieblemont C, Gisselbrecht C. Second\_line treatment paradigms for diffuse large B<sub>2</sub> cell lymphomas. *Curr Oncol Rep*. 2009 Sep;11(5):386\_93. Review. Ribrag V, Gisselbrecht C, Haioun C, Salles G, Golfier JB, Ertault M, Ferme C, Briere J, Brice P, Mounier N. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B<sub>2</sub> cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). *Cancer*. 2009 Oct 1;115(19):4540\_6. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. *J Clin Oncol*. 2009 Aug 10;27(23):3822\_9. Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morschhauser F, Gisselbrecht C. Rituximab versus observation after high\_dose consolidative first\_line chemotherapy with autologous stem\_cell transplantation in patients with poor\_risk diffuse large B<sub>2</sub> cell lymphoma. *Ann Oncol*. 2009 Dec;20(12):1985\_92. Dupuis J, Itti E, Rahmouni A, Hemery F, Gisselbrecht C, Lin C, Copie\_Bergman C, Belhadj K, El Gnaoui T, Gaillard I, Kuhnowski F, Meignan M, Haioun C. Response assessment after an inductive CHOP or CHOP\_like regimen with or without rituximab in 103 patients with diffuse large B<sub>2</sub> cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. *Ann Oncol*. 2009 Mar;20(3):503\_7. Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie\_Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti\_Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. *Br J Haematol*. 2009 Feb;144(3):367\_75.

## Projects

focus on diffuse large B cell lymphoma: DLBCL Outcome of relapsed DLBCL and treatment CAR T Chair of the international study on relapsed DLBCL :CORAL Chairman of several phase II , phase III studies from 1987 to 2003

Advisor for several studies on other types of lymphoma. Participation in several IDMC Co\_founder of cooperative group on Lymphoma : GELA in 1987,now LYSA regulation of clinical trails with EHA

#### Memberships

memberships: American Society of Clinical Oncology, American Society of Cancer Research, Société Française d'Hématologie, International Society of Hematology, American Society of Hematology, European Blood Marrow Transplantation honorary member, European Hematology Association. Lymphoma study association/GELA: founding member president 1987 to 2002. Member editorial board: , Clinical Lymphoma and myeloma, Haematologica, Brazilian Journal of Hematology and Hemoterapy. Faculty 1000 Galien Price member of the jury from 2013 on going Expert for EMA SAG oncology 2010 to present renewal Expert for :Drug Agency (AFSSAPS, ANSM). EMA 2010\_2020 SAG oncology Numerous invitations in international conferences: ASCO, ASH,EHA, EBMT. .... society of hematology: turkish, Japonese, chinese, corean, danish, brazil, spanish, french, german, british, italian,Irish, belgium, swiss, sweden .....

#### Other Relevant Information

Expert ONIAM